Johnson & Johnson’s Psoriasis Pill ICOTYDE® Sustains Skin Clearance in 70% of Patients Over Two Years
In a significant advancement for dermatology, Johnson & Johnson (NYSE: JNJ) has released two-year results from its Phase 3 ICONIC-TOTAL clinical trial. The data reveals that their once-daily oral psoriasis treatment, ICOTYDE® (icotrokinra), has maintained impressive skin clearance in patients with challenging plaque psoriasis.
The results were presented in a late-breaking oral session at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. The Week 112 data disclosed that 70% of patients achieved clear or almost clear skin. This rate increased from 57% at Week 16 to 70% at Week 112. More remarkably, 89% of patients with genital psoriasis achieved complete site-specific clearance, while scalp clearance reached 60% and hand/foot clearance reached 63%.
ICOTYDE is described as “the first and only targeted oral peptide” that precisely blocks the IL-23 receptor. It is approved for adults and adolescents aged 12 and older. Nail psoriasis severity also improved by 71% by Week 112, with no new safety signals identified throughout the study period.
“These robust two-year data validate that ICOTYDE provides enduring skin clearance with a favorable safety profile, making it a pivotal advancement in plaque psoriasis treatment,” stated Professor Richard B. Warren, MD, PhD, of the University of Manchester.
Source: Johnson & Johnson Press Release – October 2, 2026